Sutro Biopharma (NASDAQ:STRO) Rating Reiterated by Zacks Investment Research

Sutro Biopharma (NASDAQ:STRO)‘s stock had its “hold” rating reissued by Zacks Investment Research in a research note issued on Saturday, Zacks.com reports.

According to Zacks, “Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in South San Francisco, California. “

Several other equities research analysts have also commented on the stock. HC Wainwright set a $18.00 price target on shares of Sutro Biopharma and gave the company a “buy” rating in a report on Monday, June 24th. Cowen restated a “buy” rating on shares of Sutro Biopharma in a report on Sunday, June 16th. ValuEngine lowered shares of Sutro Biopharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Finally, Wedbush boosted their price target on shares of Sutro Biopharma from $20.00 to $22.00 and gave the company an “outperform” rating in a report on Monday, March 4th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Sutro Biopharma currently has an average rating of “Buy” and a consensus price target of $22.75.

STRO traded up $0.04 on Friday, reaching $11.38. 682,693 shares of the company traded hands, compared to its average volume of 60,537. Sutro Biopharma has a one year low of $8.50 and a one year high of $15.90. The firm has a fifty day moving average price of $11.17. The firm has a market capitalization of $260.83 million and a P/E ratio of -1.86.

Institutional investors have recently modified their holdings of the company. American International Group Inc. purchased a new position in shares of Sutro Biopharma in the 4th quarter worth approximately $38,000. Deutsche Bank AG purchased a new position in shares of Sutro Biopharma in the 4th quarter worth approximately $87,000. Spark Investment Management LLC purchased a new position in shares of Sutro Biopharma in the 1st quarter worth approximately $168,000. SG Americas Securities LLC purchased a new position in shares of Sutro Biopharma in the 4th quarter worth approximately $169,000. Finally, Geode Capital Management LLC purchased a new position in shares of Sutro Biopharma in the 4th quarter worth approximately $456,000. 49.00% of the stock is currently owned by hedge funds and other institutional investors.

About Sutro Biopharma

Sutro Biopharma, Inc operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers.

Further Reading: Golden Cross

Get a free copy of the Zacks research report on Sutro Biopharma (STRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Sutro Biopharma (NASDAQ:STRO)

Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.